156 related articles for article (PubMed ID: 28454342)
1. Feasibility and antitumor efficacy
Cervantes-Madrid D; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Oncol Lett; 2017 Mar; 13(3):1905-1910. PubMed ID: 28454342
[TBL] [Abstract][Full Text] [Related]
2. A combination of inhibitors of glycolysis, glutaminolysis and
Schcolnik-Cabrera A; Dominguez-Gómez G; Chávez-Blanco A; Ramírez-Yautentzi M; Morales-Bárcenas R; Chávez-Díaz J; Taja-Chayeb L; Dueáas-González A
Oncol Lett; 2019 Dec; 18(6):6909-6916. PubMed ID: 31788130
[TBL] [Abstract][Full Text] [Related]
3. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Lai D; Hua S; Tovar AR; Diaz-Chavez J; Duenas-Gonzalez A
Oncol Lett; 2020 Sep; 20(3):3053-3060. PubMed ID: 32782623
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
Cervantes-Madrid D; Dueñas-González A
Oncol Rep; 2015 Sep; 34(3):1533-42. PubMed ID: 26134042
[TBL] [Abstract][Full Text] [Related]
5. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
6. Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer.
Schcolnik-Cabrera A; Dueñas-Gonzalez A
Methods Mol Biol; 2021; 2174():45-69. PubMed ID: 32813244
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Vargas-Castillo A; Ponce-Toledo RI; Lai D; Hua S; Tovar AR; Torres N; Perez-Montiel D; Diaz-Chavez J; Duenas-Gonzalez A
Sci Rep; 2021 Mar; 11(1):5222. PubMed ID: 33664364
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
[TBL] [Abstract][Full Text] [Related]
9. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON).
Kulkarni RM; Dakoulas EW; Miller KE; Terse PS
Toxicol Mech Methods; 2017 Sep; 27(7):518-527. PubMed ID: 28552037
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
12. Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.
Alt J; Potter MC; Rojas C; Slusher BS
Anal Biochem; 2015 Apr; 474():28-34. PubMed ID: 25584882
[TBL] [Abstract][Full Text] [Related]
13. Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer.
Zhang GQ; Xi C; Ju NT; Shen CT; Qiu ZL; Song HJ; Luo QY
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38386265
[TBL] [Abstract][Full Text] [Related]
14. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
15. Limb development in mouse embryos: protection against teratogenic effects of 6-diazo-5-ox-L-norleucine (DON) in vivo and in vitro.
Greene RM; Kochhar DM
J Embryol Exp Morphol; 1975 Apr; 33(2):355-70. PubMed ID: 1176851
[TBL] [Abstract][Full Text] [Related]
16. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
17. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
[TBL] [Abstract][Full Text] [Related]
19. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
[TBL] [Abstract][Full Text] [Related]
20. The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
Kisner DL; Catane R; Muggia FM
Recent Results Cancer Res; 1980; 74():258-63. PubMed ID: 7192426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
